THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 摘要 胰高血糖素抑制剂普兰林肽和艾塞那肽在成人T2 DM患者中的使用已得到充分证实，但缺乏关于儿童T2 DM有效降糖作用的信息。我们实验室先前的研究表明，T2 DM儿童中存在未减轻的早期餐后高胰高血糖素血症，导致显著的餐后高血糖。需要胰岛素治疗的T2 DM儿童存在胰岛素、胰淀素和GLP-1缺乏。胰淀素和GLP-1都是有效的内源性胰高血糖素抑制剂。将在需要胰岛素的T2 DM儿童中检测胰淀素类似物普兰林肽和GLP-1受体激动剂依塞那肽的降糖和降胰高血糖素作用。将使用最低成人推荐剂量。随着儿童人群中T2 DM发病率的增加，我们有责任研究新的治疗方法，以改善血糖控制并预防与糖尿病相关的长期微血管和大血管并发症。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT The use of glucagon suppressors pramlintide and exenatide is well established in adult patients with T2DM, but there is a lack of information regarding an effective glucose lowering effect in pediatric T2DM. Previous studies from our laboratory showed that there is unabated early postprandial hyperglucagonemia in children with T2DM contributing to the marked postprandial hyperglycemia. There is insulin, amylin and GLP-1 deficiency in children with T2DM requiring insulin therapy. Both amylin and GLP-1 are potent endogenous glucagon suppressors. The glucose and glucagon lowering effect of the amylin analog pramlintide and the GLP-1 receptor agonist exenatide will be tested in insulin requiring children with T2DM. The lowest adult recommended doses would be used. With an increasing incidence of T2DM in the pediatric population, it is incumbent upon us to research new therapies in an effort to improve glycemic control and prevent the long-term micro and macrovascular complications associated with diabetes.